【药物名称】AR-C85095MX
化学结构式(Chemical Structure):
参考文献No.52331
标题:Novel phosphate cpds. and their use as medicaments
作者:Meghani, P.; Kindon, N.; Thom, S. (AstraZeneca AB; AstraZeneca plc)
来源:WO 9845309
合成路线图解说明:

Regioselective lithiation of the tris-O-silylated uridine (I) with sec-butyllithium in the presence of TMEDA, followed by addition to dibenzosuberenone (II) afforded the 5-(dibenzocycloheptenyl)uridine derivative (III). Subsequent reduction of the tertiary alcohol of (III) with triethylsilane in the presence of boron trifluoride, followed by re silylation with tert-butyldimethylsilyl chloride furnished (IV). The 4-thiouridine derivative (V) was then obtained by thionation of (IV) with phosphorus pentasulfide in refluxing pyridine. Removal of the O-silyl protecting groups of (V) was effected by treatment with HF-pyridine, yielding (VI). Phosphorylation of the primary hydroxyl of (VI) with phosphoryl chloride in the presence of 1,8-bis-(dimethylamino)naphthalene in trimethyl phosphate, followed by condensation with dichloromethylenebisphosphonic acid gave rise to the target triphosphate analogue, which was finally converted to the corresponding tetrasodium salt by passage through a cation-exchange resin.

参考文献No.641421
标题:SAR leading to the discovery of AR-C 85095MX, a potent and selective P2Y2 antagonist
作者:Kindon, N.; Jewel, R.; Johnson, T.; McInally, J.; Meghani, P.; Thom, S.
来源:11th RSC-SCI Med Chem Symp (Sept 9 2001, Cambridge) 2001,Abst P8
合成路线图解说明:

Regioselective lithiation of the tris-O-silylated uridine (I) with sec-butyllithium in the presence of TMEDA, followed by addition to dibenzosuberenone (II) afforded the 5-(dibenzocycloheptenyl)uridine derivative (III). Subsequent reduction of the tertiary alcohol of (III) with triethylsilane in the presence of boron trifluoride, followed by re silylation with tert-butyldimethylsilyl chloride furnished (IV). The 4-thiouridine derivative (V) was then obtained by thionation of (IV) with phosphorus pentasulfide in refluxing pyridine. Removal of the O-silyl protecting groups of (V) was effected by treatment with HF-pyridine, yielding (VI). Phosphorylation of the primary hydroxyl of (VI) with phosphoryl chloride in the presence of 1,8-bis-(dimethylamino)naphthalene in trimethyl phosphate, followed by condensation with dichloromethylenebisphosphonic acid gave rise to the target triphosphate analogue, which was finally converted to the corresponding tetrasodium salt by passage through a cation-exchange resin.

Drug Information Express,Drug R&D,Chemical Database,Patent Search.
Copyright © 2006-2024 Drug Future. All rights reserved.Contact Us